Ocular Hypertension Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

The "Ocular Hypertension Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Ocular Hypertension - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

Ocular Hypertension Epidemiology

The epidemiology division's Ocular Hypertension symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Ocular Hypertension epidemiology segmented as the Prevalent cases of Ocular Hypertension , Gender-specific prevalent case of Ocular Hypertension, Age-specific prevalent cases of Ocular Hypertension and Treated- cases of Ocular Hypertension. The report includes the prevalent scenario of Ocular Hypertension symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Ocular Hypertension (OHT) Epidemiology

The epidemiology segment also provides the Ocular Hypertension (OHT) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Ocular Hypertension in the 7MM were 20,817,647 in 2020.

Ocular Hypertension Drug Chapters

The drug chapter segment of the Ocular Hypertension report encloses the detailed analysis of Ocular Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Ocular Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Prostaglandin analogs (PGAs) are recommended as the first-choice treatment for POAG because of their efficacy, limited systemic side effects, and once-daily dosing. These drugs reduce IOP by stimulating aqueous humor drainage, primarily through the uveoscleral outflow pathway. Latanoprost, bimatoprost, travoprost, and tafluprost, all PGF2a analogues, are currently approved for glaucoma therapy in the US and EU. Beta blockers, combination therapies, carbonic anhydrase inhibitors constitute second line of therapy for treatment of OHT.

Ocular Hypertension Emerging Drugs

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently being developed by Nicox Ophthalmics in Phase II multicenter, clinical study for the lowering of IOP in patients with OAG or OHT in the US.

Ocular Hypertension Market Outlook

The Ocular Hypertension market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Ocular Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Ocular Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

This section includes a glimpse of the Ocular Hypertension (OHT) market in 7MM. The market size of OHT in the seven major markets was found to be USD 2,735.0 million in 2020 and market is estimated to increase at a CAGR of 3.82% for the study period (2018-2030).

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Ocular Hypertension Market Overview at a Glance

3.1 Market Share (%) Distribution of Ocular Hypertension in 2018

3.2 Market Share (%) Distribution of Ocular Hypertension in 2030

4 Executive Summary of Ocular Hypertension

5 Disease Background and Overview

5.1 Introduction

5.2 Causes

5.3 Physiology and pathogenesis

5.4 Morphology

5.5 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of OHT

6.3 Assumption and Rationale

6.4 The United States

6.4.1 Prevalent Cases of Ocular Hypertension in the United States

6.4.2 Gender-specific Prevalence of Ocular Hypertension in the United States

6.4.3 Age-specific Prevalence of Ocular Hypertension in the United States

6.4.4 Treated cases of Ocular Hypertension in the United States

6.5 EU5

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 United Kingdom

6.6 Japan

7 Treatment

7.1 Frequency and follow-up

7.2 Uncertainties regarding best practice for managing ocular hypertension

7.3 Progression to Glaucoma

8 NICE Recommendations and Guidelines

8.1 Case-finding

8.2 Diagnosis

8.3 Standard practice for all assessments

8.4 Reassessment tests

8.5 Treatment

8.6 Stopping treatment for people with OHT or suspected COAG

9 Patient Journey

10 Case Reports

11 Marketed Therapies

11.1 Key Cross- Marketed therapies

11.2 Travoprost ophthalmic solution: Novartis

11.3 Vyzulta (latanoprostene bunod ophthalmic solution): Bausch and Lomb Incorporated

11.4 Zioptan: Merck Sharp and Dohme

11.5 Rhopressa: Aerie Pharmaceuticals

11.6 DURYSTA: Abbvie

11.7 Rocklatan: Aerie Pharmaceutical

11.8 LUMIGAN: Allergan plc

11.9 Betaxon: Alcon Laboratories, Inc.

11.1 COSOPT: Merck Sharp & Dohme Corp.

11.11 Rescula: Ciba Vision

11.12 Alphagan P: Abbvie

11.13 Xelpros: Sun Pharma Advanced Research Company Limited

11.14 Tapcom/ DE-111: Santen Pharmaceutical Co., Ltd.

11.15 Simbrinza: Alcon Research

11.16 GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa Ltd.

11.17 DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research

11.18 Combigan: Allergan

11.19 Azarga: Novartis

11.2 Ganfort: Allergan

11.21 Mikeluna: Otsuka Pharmaceuticals

11.22 AILAMIDE: Senju Pharmaceuticals

11.23 Aibeta: Senju Pharmaceuticals

12 Emerging Therapies

12.1 DE-130A (latanoprost): Santen Pharmaceutical

12.2 NCX 470: Nicox Ophthalmics

12.3 Bamosiran (SYL040012): Sylentis

12.4 Nyxol (Phentolamine Mesylate): Ocuphire Pharma

12.5 POLAT-001: Peregrine Ophthalmic

12.6 Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical

12.7 ENV515 (Travoprost XR): Envisia Therapeutics

12.8 PRO-122: Laboratorios Sophia S.A de C.V.

12.9 DE-117: Santen Inc.

12.10 PDP-716: Sun Pharma

12.11 QLS-101: Qlaris Bio

12.12 ST266: Noveome

13 Ocular Hypertension: 7 Major Market Analysis

13.1 Key Findings

13.2 Market Size of Ocular Hypertension in 7MM

13.3 Market Size of Ocular Hypertension by Therapies by class

13.4 Market Size of Ocular Hypertension for Emerging Therapies by class

13.5 Market Outlook

14 Market Drivers

15 Market Barriers

16 SWOT Analysis

17 Unmet Needs

18 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/875kg1

View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005499/en/